Banner

The TOBY™ platform is advancing noninvasive cancer detection through urine-based volatile organic compound profiling, mass spectrometry, and artificial intelligence.

Research

3D colorful grid-like structure with varying heights, displaying a rainbow spectrum across its surface.

Text + image

<h2 style="white-space:pre-line">New Publication in Cancer Reports</h2>
<p>TOBY’s study explored AI analysis of urinary VOCs for detecting 10 cancers. Read the peer-reviewed findings.</p>

Cancer Reports publication on TOBY’s urine based multi cancer detection study.

Video

Highlights from TOBY’s blinded, prospective study evaluating urine-based VOC technology for prostate cancer detection, including low-PSA and MRI-invisible disease

TOBY Presents Prostate Cancer Results in Kyoto

<h1 style="white-space:pre-line">Duke-Led Prostate Cancer Study</h1>
<p>Duke-Led Prostate Cancer A prospective study evaluated TOBY’s urine VOC test in 84 men referred for prostate biopsy. The findings were presented at AUA 2026 and the Focal Therapy Society 2026 meeting.</p>
<h3>Conference Presentations</h3>
<p>AUA 2026 | Abstract ID: 26-7999</p>
<p>Focal Therapy Society 2026 | Abstract ID: FO2-6</p>
<p>Engineering and Urology Society 2026 | Poster #33</p>

Contact form

<h3>Be part of the movement for early detection via mass spectrometry of urine and artificial intelligence</h3>

name

email

I'm a

Patient

Healthcare Professional

Laboratory Professional

Investor

Other

message

TOBY

TOBY is a diagnostics platform using VOC analysis, spectroscopy, and AI to deliver early, noninvasive disease detection. Our first application, TOBY Oncology, is developing a simple urine test for early cancer detection.

Raleway

Cabin

<p>Read TOBY’s <a title="Peer-Reviewed Publication in Cancer Reports" href="https://onlinelibrary.wiley.com/doi/10.1002/cnr2.70735" target="_blank" rel="noopener">new publication in Cancer Reports</a>.</p>